Does OncuraKit have higher value for high-risk populations?

Yes — the clinical value of any screening test is higher when used in populations with higher prior probability of disease. OncuraKit provides the greatest clinical benefit for: adults over 60 (approximately 1 in 100 are likely to develop cancer), people with a significant family history of cancer (2× to 10× higher risk depending on cancer type and number of affected relatives), people who have received inconclusive results from standard screenings (PSA, mammogram, colonoscopy), people with known cancer predisposition syndromes (BRCA1/2, Lynch syndrome, Li-Fraumeni), current or former heavy smokers (elevated lung and head/neck cancer risk), and individuals with occupational carcinogen exposure (asbestos, benzene, vinyl chloride). In these populations, the benefit-to-risk ratio of proactive screening is highest.